<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> is a systemic <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue disorder</z:e> caused by mutations in the fibrillin-1 gene </plain></SENT>
<SENT sid="1" pm="."><plain>It was originally believed that <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> results exclusively from the production of abnormal fibrillin-1 that leads to structurally weaker connective tissue when incorporated into the extracellular matrix </plain></SENT>
<SENT sid="2" pm="."><plain>This effect seemed to explain many of the clinical features of <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e>, including <z:hpo ids='HP_0002616'>aortic root dilatation</z:hpo> and <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002647'>aortic dissection</z:hpo>, which represent the main causes of morbidity and mortality in <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Recent molecular studies, most based on genetically defined mouse models of <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e>, have challenged this paradigm </plain></SENT>
<SENT sid="4" pm="."><plain>These studies established the critical contribution of fibrillin-1 haploinsufficiency and dysregulated transforming growth factor-beta signaling to disease progression </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: It seems that many manifestations of <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> are less related to a primary structural deficiency of the tissues than to altered morphogenetic and homeostatic programs that are induced by altered transforming growth factor-beta signaling </plain></SENT>
<SENT sid="6" pm="."><plain>Most important, transforming growth factor-beta antagonism, through transforming growth factor-beta neutralizing antibodies or <z:chebi fb="0" ids="6541">losartan</z:chebi> (an <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> type 1 receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>), has been shown to prevent and possibly reverse <z:hpo ids='HP_0002616'>aortic root dilatation</z:hpo>, <z:hpo ids='HP_0001634'>mitral valve prolapse</z:hpo>, <z:e sem="disease" ids="C0024115" disease_type="Disease or Syndrome" abbrv="">lung disease</z:e>, and skeletal muscle dysfunction in a mouse model of <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: There are indicators that <z:chebi fb="0" ids="6541">losartan</z:chebi>, a drug widely used to treat arterial <z:hpo ids='HP_0000822'>hypertension</z:hpo> in humans, offers the first potential for primary prevention of clinical manifestations in <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> </plain></SENT>
</text></document>